Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia (original) (raw)

• Kurzrock, R., Gutterman, J. & Talpaz, M. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319, 990–998 (1988).
  Article CAS PubMed Google Scholar
• Goldman, J. M. & Druker, B. J. Chronic myeloid leukemia: current treatment options. Blood 98, 2039–2042 (2001).
  Article CAS PubMed Google Scholar
• Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 23 Dec 2004 (10.1182/blood-2004-08-3097).
• Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nature Med. 2, 561–566 (1996).
  Article CAS PubMed Google Scholar
• Deininger, M. W., Goldman, J. M., Lydon, N. & Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR–ABL-positive cells. Blood 90, 3691–3698 (1997).
  CAS PubMed Google Scholar
• Deininger, M. W. et al. BCR–ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 60, 2049–2055 (2000).
  CAS PubMed Google Scholar
• le Coutre, P. et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl Cancer Inst. 91, 163–168 (1999).
  Article CAS PubMed Google Scholar
• Druker, B. J., O'Brien, S. G., Cortes, J. & Radich, J. Chronic myelogenous leukemia. Hematology (Am. Soc. Hematol. Educ. Program) 111–135 (2002).
• Stentoft, J. et al. Kinetics of BCR–ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur. J. Haematol. 67, 302–308 (2001).
  Article CAS PubMed Google Scholar
• Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701–4707 (2003).
  Article CAS PubMed Google Scholar
• Lowenberg, B. Minimal residual disease in chronic myeloid leukemia. N. Engl. J. Med. 349, 1399–1401 (2003).
  Article PubMed Google Scholar
• Gorre, M. E. & Sawyers, C. L. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr. Opin. Hematol. 9, 303–307 (2002). A comprehensive review on the molecular mechanisms of imatinib resistance in CML.
  Article PubMed Google Scholar
• Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR_–_ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS PubMed Google Scholar
• Weisberg, E. & Griffin, J. D. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist. Updat. 6, 231–238 (2003).
  Article CAS PubMed Google Scholar
• Woodring, P. J., Hunter, T. & Wang, J. Y. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J. Cell Sci. 116, 2613–2626 (2003).
  Article CAS PubMed Google Scholar
• Hernandez, S. E., Krishnaswami, M., Miller, A. L. & Koleske, A. J. How do Abl family kinases regulate cell shape and movement? Trends Cell Biol. 14, 36–44 (2004).
  Article CAS PubMed Google Scholar
• Schwartzberg, P. L. et al. Mice homozygous for the ablm1 mutation show poor viaility and depletion of selected B and T cell populations. Cell 65, 1165–1175 (1991).
  Article CAS PubMed Google Scholar
• Tybulewicz, V. L. J., Crawford, C. E., Jackson, P. K., Bronson, R. T. & Mulligan, R. C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153–1163 (1991).
  Article CAS PubMed Google Scholar
• Koleske, A. J. et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 21, 1259–1272 (1998).
  Article CAS PubMed Google Scholar
• Voncken, J. W. et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell 80, 719–728 (1995).
  Article CAS PubMed Google Scholar
• Ren, R. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene 21, 8629–8642 (2002).
  Article CAS PubMed Google Scholar
• Ramaraj, P. et al. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res. 64, 5322–5331 (2004).
  Article CAS PubMed Google Scholar
• Zhao, R. C., Jiang, Y. & Verfaillie, C. M. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector. Blood 97, 2406–2412 (2001).
  Article CAS PubMed Google Scholar
• Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824–830 (1990).
  Article CAS PubMed Google Scholar
• Kelliher, M. A., McLaughlin, J., Witte, O. N. & Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl Acad. Sci. USA 87, 6649–6653 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Elefanty, A. G., Hariharan, I. K. & Cory, S. bcr–abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9, 1069–1078 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Hawley, R. G. High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells. Ann. NY Acad. Sci. 716, 327–330 (1994).
  Article CAS PubMed Google Scholar
• Cherry, S. R., Biniszkiewicz, D., van Parijs, L., Baltimore, D. & Jaenisch, R. Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol. Cell. Biol. 20, 7419–7426 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, X. & Ren, R. Bcr–Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92, 3829–3840 (1998).
  CAS PubMed Google Scholar
• Pear, W. S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780–3792 (1998).
  CAS PubMed Google Scholar
• Li, S., Ilaria, R. L., Million, R. P., Daley, G. Q. & Van Etten, R. A. The p190, p210, and p230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399–1412 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Heisterkamp, N., Jenster, G., Kioussis, D., Pattengale, P. K. & Groffen, J. Human bcr_–_abl gene has a lethal effect on embryogenesis. Transgenic Res. 1, 45–53 (1991).
  Article CAS PubMed Google Scholar
• Castellanos, A. et al. A BCR–ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood 90, 2168–2174 (1997).
  CAS PubMed Google Scholar
• Heisterkamp, N. et al. Acute leukemia in bcr/abl transgenic mice. Nature 344, 251–253 (1990).
  Article CAS PubMed Google Scholar
• Voncken, J. W. et al. Restricted oncogenicity of BCR/ABL p190 in transgenic mice. Cancer Res. 52, 4534–4539 (1992).
  CAS PubMed Google Scholar
• Voncken, J. W. et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86, 4603–4611 (1995).
  CAS PubMed Google Scholar
• Honda, H. et al. Expression of p210bcr–abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood 85, 2853–2861 (1995).
  CAS PubMed Google Scholar
• Huettner, C. S., Zhang, P., Van Etten, R. A. & Tenen, D. G. Reveribility of acute B-cell leukemia induced by BCR–ABL1. Nature Genet. 24, 57–60 (2000).
  Article CAS PubMed Google Scholar
• Huettner, C. S. et al. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood 102, 3363–3370 (2003).
  Article CAS PubMed Google Scholar
• Koschmieder, S. et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR–ABL leukaemogenesis. Blood 105, 324–334 (2005).
  Article CAS PubMed Google Scholar
• Faderl, S. et al. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341, 164–172 (1999).
  Article CAS PubMed Google Scholar
• Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343–3356 (2000).
  CAS PubMed Google Scholar
• Ahuja, H. G., Popplewell, L., Tcheurekdjian, L. & Slovak, M. L. NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia. Genes Chromosom. Cancer 30, 410–415 (2001).
  Article CAS PubMed Google Scholar
• Colovic, M., Jankovic, G., Bila, J., Djordjevic, V. & Wiernik, P. H. Inversion of chromosome 16 in accelerated phase of chronic myeloid leukaemia: report of a case and review of the literature. Med. Oncol. 15, 199–201 (1998).
  Article CAS PubMed Google Scholar
• de Bruijn, M. F. & Speck, N. A. Core-binding factors in hematopoiesis and immune function. Oncogene 23, 4238–4248 (2004).
  Article CAS PubMed Google Scholar
• Hirai, H. The transcription factor Evi-1. Int. J. Biochem. Cell Biol. 31, 1367–1371 (1999).
  Article CAS PubMed Google Scholar
• Ihle, J. N., Morishita, K., Matsugi, T. & Bartholomew, C. Insertional mutagenesis and transformation of hematopoietic stem cells. Prog. Clin. Biol. Res. 352, 329–337 (1990).
  CAS PubMed Google Scholar
• Cuenco, G. M., Nucifora, G. & Ren, R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a novel model for human AML. Proc. Natl Acad. Sci. USA 97, 1760–1765 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Cuenco, G. M. & Ren, R. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 20, 8236–8248 (2001). The first report of cooperation of BCR–ABL and an oncogenic transcription factor in induction of a myeloblastic leukaemia in mice. Together, these factors block myeloid differentiation, transforming CML from the chronic phase to blast phase.
  Article CAS PubMed Google Scholar
• Dash, A. B. et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc. Natl Acad. Sci. USA 99, 7622–7627 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Jamieson, C. H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657–667 (2004). Reported that GMPs in blast-phase CML undergo self renewal. The results indicate that GMPs are transformed into leukaemic stem cells during blast-phase CML.
  Article CAS PubMed Google Scholar
• Ghaffari, S., Daley, G. Q. & Lodish, H. F. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia 13, 1200–1206 (1999).
  Article CAS PubMed Google Scholar
• Ren, R. Modeling the dosage effect of oncogenes in leukaemogenesis. Curr. Opin. Hematol. 11, 25–34 (2004).
  Article PubMed Google Scholar
• Gross, A. W., Zhang, X. & Ren, R. Bcr–Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an sh3 deletion induces only lymphoid malignancy. Mol. Cell. Biol. 19, 6918–6928 (1999). Showed that activation of the ABL kinase activity is not sufficient for BCR–ABL to induce CML-like disease in mice.
  Article CAS PubMed PubMed Central Google Scholar
• Gross, A. W. & Ren, R. Bcr–Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells in vivo. Oncogene 19, 6286–6296 (2000).
  Article CAS PubMed Google Scholar
• McWhirter, J. R., Gaalasso, D. L. & Wang, J. Y. J. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr–Abl oncoproteins. Mol. Cell. Biol. 13, 7587–7595 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, X., Subrahmanyam, R., Wong, R., Gross, A. W. & Ren, R. The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr–Abl. Mol. Cell. Biol. 21, 840–853 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• He, Y. et al. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99, 2957–5768 (2002).
  Article CAS PubMed Google Scholar
• Smith, K. M., Yacobi, R. & Van Etten, R. A. Autoinhibition of Bcr–Abl through its SH3 domain. Mol. Cell 12, 27–37 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Pendergast, A. M. et al. BCR–ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein. Cell 75, 175–185 (1993).
  Article CAS PubMed Google Scholar
• Puil, L. et al. Bcr–Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13, 764–773 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Sattler, M. et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1, 479–492 (2002). Described the critical role of GAB2 in mediating the ability of BCR–ABL to confer cytokine-independent growth of primary myeloid cells.
  Article CAS PubMed Google Scholar
• Million, R. P. & Van Etten, R. A. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96, 664–670 (2000).
  CAS PubMed Google Scholar
• Goga, A., McLaughlin, J., Afar, D. E., Saffran, D. C. & Witte, O. N. Alternative signals to RAS for hematopoietic transformation by the Bcr–Abl oncogene. Cell 82, 981–988 (1995).
  Article CAS PubMed Google Scholar
• Zhang, X., Wong, R., Hao, S. X., Pear, W. S. & Ren, R. The SH2 domain of bcr–Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood 97, 277–287 (2001).
  Article CAS PubMed Google Scholar
• Roumiantsev, S., de Aos, I. E., Varticovski, L., Ilaria, R. L. & Van Etten, R. A. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukaemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97, 4–13 (2001).
  Article CAS PubMed Google Scholar
• Prywes, R., Foulkes, J. G., Rosenberg, N. & Baltimore, D. Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation. Cell 34, 569–579 (1983).
  Article CAS PubMed Google Scholar
• Wertheim, J. A. et al. Localization of BCR–ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood 102, 2220–2228 (2003).
  Article CAS PubMed Google Scholar
• Dai, Z., Kerzic, P., Schroeder, W. G. & McNiece, I. K. Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukaemogenesis. J. Biol. Chem. 276, 28954–28960 (2001).
  Article CAS PubMed Google Scholar
• Nieborowska-Skorska, M., Hoser, G., Kossev, P., Wasik, M. A. & Skorski, T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukaemogenesis. Blood 99, 4531–4539 (2002).
  Article CAS PubMed Google Scholar
• Wong, S. & Witte, O. N. The BCR–ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247–306 (2004).
  Article CAS PubMed Google Scholar
• Jiang, X., Lopez, A., Holyoake, T., Eaves, A. & Eaves, C. Autocrine production and action of IL-3 and granulocyte colony- stimulating factor in chronic myeloid leukemia. Proc. Natl Acad. Sci. USA 96, 12804–12809 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Sexl, V. et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 96, 2277–2283 (2000).
  CAS PubMed Google Scholar
• Dinulescu, D. M. et al. c-CBL is not required for leukemia induction by Bcr–Abl in mice. Oncogene 22, 8852–8860 (2003).
  Article CAS PubMed Google Scholar
• Li, S. et al. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 97, 1442–1450 (2001).
  Article CAS PubMed Google Scholar
• Hu, Y. et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR–ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genet. 36, 453–461 (2004).
  Article CAS PubMed Google Scholar
• Ptasznik, A., Nakata, Y., Kalota, A., Emerson, S. G. & Gewirtz, A. M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR–ABL1+ leukemia cells. Nature Med. 10, 1187–1189 (2004).
  Article CAS PubMed Google Scholar
• Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
  Article CAS Google Scholar
• Tartaglia, M. et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature Genet. 29, 465–468 (2001).
  Article CAS PubMed Google Scholar
• Tartaglia, M. et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genet. 34, 148–150 (2003).
  Article CAS PubMed Google Scholar
• Kosaki, K. et al. PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J. Clin. Endocrinol. Metab. 87, 3529–3533 (2002).
  Article CAS PubMed Google Scholar
• Neel, B. G., Gu, H. & Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284–293 (2003).
  Article CAS PubMed Google Scholar
• Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
  CAS PubMed Google Scholar
• Braun, B. S. et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl Acad. Sci. USA 101, 597–602 (2004).
  Article CAS PubMed Google Scholar
• Chan, I. T. et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J. Clin. Invest. 113, 528–538 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307–317 (1996). Reported the striking discovery that Icsbp -null mice develop of a CML-like disease, indicating that this protein is a tumour suppressor.
  Article CAS PubMed Google Scholar
• Tamura, T., Nagamura-Inoue, T., Shmeltzer, Z., Kuwata, T. & Ozato, K. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 13, 155–165 (2000).
  Article CAS PubMed Google Scholar
• Hao, S. X. & Ren, R. Expression of ICSBP is downregulated in Bcr–Abl-induced murine CML-like disease, and forced coexpression of ICSBP inhibits the Bcr–Abl-induced myeloproliferative disorder. Mol. Cell. Biol. 20, 1149–1161 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Schmidt, M. et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91, 22–29 (1998).
  CAS PubMed Google Scholar
• Schorpp-Kistner, M., Wang, Z. Q., Angel, P. & Wagner, E. F. JunB is essential for mammalian placentation. EMBO J. 18, 934–948 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Passegue, E., Jochum, W., Schorpp-Kistner, M., Mohle-Steinlein, U. & Wagner, E. F. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 104, 21–32 (2001). Showed that specific inactivation of JUNB in haematopoietic cells led to the development of a CML-like disease in mice. The results indicate that JUNB is a tumour suppressor.
  Article CAS PubMed Google Scholar
• Passegue, E., Wagner, E. F. & Weissman, I. L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119, 431–443 (2004). Reported that induction of CML-like disease by JUNB inactivation only occurs in JUNB-deficient long-term self-renewing haematopoietic stem cells. The results indicated the haematopoietic stem-cell origin of CML.
  Article CAS PubMed Google Scholar
• Bruchova, H., Borovanova, T., Klamova, H. & Brdicka, R. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk. Lymphoma 43, 1289–1295 (2002).
  Article CAS PubMed Google Scholar
• Yang, M. Y., Liu, T. C., Chang, J. G., Lin, P. M. & Lin, S. F. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 101, 3205–3211 (2003).
  Article CAS PubMed Google Scholar
• Ishida, D. et al. Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell 4, 55–65 (2003). Described the targeted inactivation of SIPA1, which led to the development of a CML-like disease in mice.
  Article CAS PubMed Google Scholar
• Stork, P. J. Does Rap1 deserve a bad Rap? Trends Biochem. Sci. 28, 267–275 (2003).
  Article CAS PubMed Google Scholar
• Mizuchi, D. et al. BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. Biochem. Biophys. Res. Commun. 326, 645–651 (2005).
  Article CAS PubMed Google Scholar
• Helgason, C. D. et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12, 1610–1620 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Sattler, M. et al. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol. Cell. Biol. 19, 7473–7480 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Jiang, X. et al. Evidence for a positive role of SHIP in the BCR–ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 102, 2976–2984 (2003).
  Article CAS PubMed Google Scholar
• Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319–325 (2002).
  Article CAS PubMed Google Scholar
• Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014–1018 (2002).
  Article CAS PubMed Google Scholar
• Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792–3800 (2002).
  Article CAS PubMed Google Scholar
• Wertheim, J. A. et al. BCR–ABL-induced adhesion defects are tyrosine kinase-independent. Blood 99, 4122–4130 (2002). Showed that ABL-kinase-deficient BCR–ABL retains the ability to dysregulate cell adhesion.
  Article CAS PubMed Google Scholar
• Huntly, B. J. et al. MOZ–TIF2, but not BCR–ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004). Demonstrated that some, but not all, leukaemia-associated oncogenes could confer properties of leukaemic stem cells to haematopoietic progenitors destined to undergo apoptosis.
  Article CAS PubMed Google Scholar
• Yoshida, C. & Melo, J. V. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int. J. Hematol. 79, 420–433 (2004).
  Article CAS PubMed Google Scholar
• Goldman, J. M. Chronic myeloid leukemia-still a few questions. Exp. Hematol. 32, 2–10 (2004).
  Article PubMed Google Scholar
• Skorski, T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21, 8591–8604 (2002).
  Article CAS PubMed Google Scholar
• Holyoake, T. L., Jiang, X., Drummond, M. W., Eaves, A. C. & Eaves, C. J. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 16, 549–558 (2002).
  Article CAS PubMed Google Scholar
• Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).
  Article CAS PubMed Google Scholar
• Sawyers, C. L. et al. Hematologic and cytogenetic responses in Imatinib-resistant chronic phase chronic myelogenous leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study. Blood 104, 4a (2004).
  Article Google Scholar
• Vigneri, P. & Wang, J. Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase. Nature Med. 7, 228–234 (2001).
  Article CAS PubMed Google Scholar
• McWhirter, J. R. & Wang, J. Y. J. An actin-binding function contributes to transformation by the Bcr–Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J. 12, 1533–1546 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Vickers, M. Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data. Br. J. Haematol. 94, 1–4 (1996).
  Article CAS PubMed Google Scholar
• Lichtman, M. Chronic myelogenous leukemia and related disorders. in Williams Helatology (eds Beutler, E., Lichtman, M. A., Coller, B. S. & Kipps, T. J.) 298–324 (McGraw–Hill, New York, 1995).
  Google Scholar
• Biernaux, C., Loos, M., Sels, A., Huez, G. & Stryckmans, P. Detection of major bcr_–_abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86, 3118–3122 (1995).
  CAS PubMed Google Scholar
• Bose, S., Deininger, M., Gora-Tybor, J., Goldman, J. M. & Melo, J. V. The presence of typical and atypical BCR_–_ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92, 3362–3367 (1998).
  CAS PubMed Google Scholar
• Takahashi, N., Miura, I., Saitoh, K. & Miura, A. B. Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 92, 4758–4763 (1998).
  CAS PubMed Google Scholar
• Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859–871 (2003).
  Article CAS PubMed Google Scholar
• Harrison, S. C. Variation on an Src-like theme. Cell 112, 737–740 (2003).
  Article CAS PubMed Google Scholar
• Hantschel, O. et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845–857 (2003).
  Article CAS PubMed Google Scholar